戊酸雌二醇联合康复治疗盆底功能障碍性疾病临床效果观察

An observation of clinical efficacy of estradiol valerate combined with pelvic floor rehabilitation for treating patients with pelvic floor dysfunction

目的:探讨戊酸雌二醇联合盆底康复技术治疗盆底功能障碍性疾病的临床效果。方法:将92例盆底功能障碍性疾病患者随机分为观察组和对照组。对照组采用盆底康复技术治疗;观察组在对照组治疗基础上,口服戊酸雌二醇(1mg/d×56d)。经会阴三维超声检测两组肛提肌裂孔各项指标;比较治疗前后的盆底肌力;采用盆底障碍影响简易问卷(PFIQ-7)评估盆底功能变化;采用性生活质量问卷(PISQ-12)评估两组性生活质量。结果:两组治疗后在静息、缩肛、Valsalva动作时的肛提肌裂孔左右径(LHLP)、前后径(LHAP)、面积(LHA)明显降低(P<0.05);且观察组低于对照组,差异有统计学意义(P<0.05);两组治疗后盆底肌力均明显改善(P<0.05);且观察组明显优于对照组(P<0.05);两组治疗后PISQ-12评分明显升高(P<0.05),PFIQ-7评分明显降低(P<0.05);治疗后,且观察组的PISQ-12评分高于对照组(P<0.05),PFIQ-7评分低于对照组(P<0.05)。结论:戊酸雌二醇能进一步提高盆底功能障碍性疾病的治疗效果。

Objective:To explore the clinical efficacy of estradiol valerate combined with pelvic floor rehabilitation for treating patients with pelvic floor dysfunction.Methods:92 patients with pelvic floor dysfunction were divided into study group and control group randomly.The patients in control group were treated by pelvic floor rehabilitation,and the patients in study group were treated by oral estradiol valerate (1mg/d) combined with pelvic floor rehabilitation.The left and right anal fissure diameter,anterior and posterior diameter and area (LHLP,LHAP and LHA),and the pelvic floor muscle strength of patients in the two groups were measured by the perineum three dimensional ultrasound and compared between before and after treatment.The pelvic floor dysfunction questionnaire (PFIQ 7) was used to assess the change of the pelvic floor function of patients.Sexual quality of life questionnaire (PISQ 12) was used to assess the sexual life quality of patients.Results:After treatment,LHLP,LHAP and LHA of patients in both groups at rest,anal contraction and Valsalva action were significantly decreased (P <0.05),and LHLP,LHAP and LHA of patients in study group were significant lower than those of patients in control group (P <0.05).The pelvic floor muscle strength of patients in both groups was improved significantly after treatment (P <0.05),and the pelvic floor muscle strength improvement of patients in study group was significant better than that of patients in control group (P < 0.05).The PISQ 12 scores of patients in both groups increased significantly after treatment,and the PISQ 12 scores of patients in study group was significant higher than that of patients in control group (P <0.05).The PFIQ 7 scores of patients in both groups was decreased significantly,and the PFIQ 7 score was significant lower than that of patients in control group(P <0.05).Conclusion:Estradiol valerate can further improve the clinical efficacy of patients with pelvic floor dysfunction.